We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Optical Biosensor Reduces Time for Sepsis Diagnosis

By LabMedica International staff writers
Posted on 12 Feb 2020
Print article
Image: Detection and quantification of procalcitonin and C‐reactive protein using detection of inflammatory biomarkers imager (DENIS) (Photo courtesy of Ecole Polytechnique Fédérale de Lausanne).
Image: Detection and quantification of procalcitonin and C‐reactive protein using detection of inflammatory biomarkers imager (DENIS) (Photo courtesy of Ecole Polytechnique Fédérale de Lausanne).
New point‐of‐care diagnostic devices are urgently needed for rapid and accurate diagnosis, particularly in the management of life‐threatening infections and sepsis, where immediate treatment is key.

A novel portable biosensor based on nanoparticle‐enhanced digital plasmonic imaging has been developed for rapid and sensitive detection of two sepsis‐related inflammatory biomarkers, procalcitonin (PCT) and C‐reactive protein (CRP) directly from blood serum.

Bioengineers from the Ecole Polytechnique Fédérale de Lausanne (Lausanne, Switzerland) and their colleagues drew on recent developments in nanotechnology and on light effects at a nanoscale to create a highly portable, easy-to-use device that can rapidly detect sepsis biomarkers in a patient's bloodstream, and their device takes just a few minutes to deliver a result, like a pregnancy test.

The device employs an optical metasurface, in this case a thin gold sheet containing arrays of billions of nanoholes. The metasurface concentrates light around the nanoholes so as to allow for exceptionally precise biomarker detection. With this type of metasurface, the team can detect sepsis biomarkers in a blood sample with nothing more than a simple LED and a standard CMOS camera. The team began by adding a solution of special nanoparticles to the sample that are designed to capture the biomarkers and then distribute this mixture on the metasurface.

The generated images are used to rapidly determine whether disease biomarkers are present in a sample and, if so, in what concentration. They used the new device to measure the blood serum levels of two important sepsis relevant biomarkers, PCT and CRP. Doctors can use this information to accelerate the triage of sepsis patients, ultimately saving lives. The device was installed at the Vall d'Hebron University Hospital (Barcelona, Spain) and used in blind tests to examine patient samples from the hospital's sepsis bank.

The authors concluded that portable digital nanoparticle‐enhanced plasmonic imager that enables rapid detection of two inflammatory sepsis‐related biomarkers, PCT and CRP. The unique nanoplasmonic mechanism through imaging of single gold nanoparticles (Au‐NPs) binding on the gold nanohole arrays (Au‐NHAs) enables highly sensitive and rapid biomarker detection directly in blood serum. The compact nanoplasmonic reader, built of inexpensive components, weighs less than 1 kg. The study was published on January 23, 2020 in the journal Small.

Related Links:
Ecole Polytechnique Fédérale de Lausanne
Vall d'Hebron University


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Blood Gas and Chemistry Analysis System
Edan i500

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.